# MedisourceRx

> Source: https://peptidewellnessusa.com/professionals/compounding-pharmacies/medisourcerx/

A 503B outsourcing facility owned by Hims & Hers that compounds injectable semaglutide — and the subject of a December 2025 FDA warning letter.

MedisourceRx is unusual in this directory: it’s a compounding facility **owned by a telehealth company**. It’s the clearest example of vertical integration in compounded GLP-1s — the brand that sells the prescription also owns the pharmacy that fills it.

## Facility & ownership

MedisourceRx is a 503B outsourcing facility in Los Alamitos, CA, listed on the FDA Registered Outsourcing Facilities list [1]. Hims & Hers acquired it in 2024: per the company’s SEC filing, “we acquired Seaview Enterprises, LLC (d/b/a MedisourceRx)… a licensed 503B compounding outsourcing facility, which compounds products primarily for Hims & Hers customers” [2]. So it is a Hims-owned subsidiary, not an independent third-party pharmacy. We could not confirm PCAB accreditation in ACHC’s registry.

## What they compound

Injectable compounded **semaglutide**, produced primarily for Hims & Hers’ weight-loss customers [2]. (Hims’ *oral* compounded semaglutide is filled by a separate pharmacy, Strive.)

## Regulatory record

MedisourceRx received an **FDA warning letter dated December 12, 2025** [3]. Per FDA, the letter centered on failures in adverse-event reporting requirements for the facility. A warning letter is a formal FDA enforcement notice over significant violations. Stated as FDA’s findings. The FDA posted a [close-out letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medisourcerx-717970-07272026) dated July 27, 2026, meaning it has evaluated MedisourceRx’s corrective actions and considers the matters in the warning letter addressed.

## The read

Worth knowing for anyone using Hims’ injectable GLP-1: the pharmacy behind it is Hims itself, and it received an FDA warning letter in December 2025, since closed out. This isn’t a pharmacy consumers choose directly — it’s the in-house supplier for one telehealth brand — but it’s the sharpest illustration of how telehealth compounded-GLP-1 supply is becoming vertically integrated.

## References

1. [FDA — Registered Outsourcing Facilities (503B) list.](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities) (accessed 2026-07-04)
2. [Hims & Hers Health, Inc. — Form 10-K (FY2024), acquisition of Seaview Enterprises, LLC (d/b/a MedisourceRx).](https://www.sec.gov/Archives/edgar/data/1773751/000177375125000062/hims-20241231.htm) (accessed 2026-07-04)
3. [FDA — Warning Letter to MedisourceRx (#717970, 2025-12-12).](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medisourcerx-717970-12122025) (accessed 2026-07-04)